Nyxoah (NASDAQ:NYXH - Free Report) had its price target reduced by Stifel Nicolaus from $15.00 to $14.00 in a research note issued to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.
Separately, HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Nyxoah in a research note on Tuesday, April 8th.
Check Out Our Latest Report on Nyxoah
Nyxoah Price Performance
Shares of NASDAQ NYXH traded down $0.05 during mid-day trading on Monday, reaching $5.87. The company's stock had a trading volume of 48,535 shares, compared to its average volume of 66,951. The stock has a 50-day moving average of $8.39 and a two-hundred day moving average of $8.96. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. The stock has a market capitalization of $199.93 million, a P/E ratio of -3.14 and a beta of 1.55. Nyxoah has a 1-year low of $5.55 and a 1-year high of $12.21.
Nyxoah (NASDAQ:NYXH - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. The business had revenue of $1.35 million for the quarter, compared to analysts' expectations of $2.02 million. On average, equities research analysts anticipate that Nyxoah will post -1.91 EPS for the current fiscal year.
Institutional Trading of Nyxoah
Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its position in Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after acquiring an additional 2,774 shares during the period. Walleye Capital LLC lifted its stake in shares of Nyxoah by 23.9% in the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock valued at $119,000 after purchasing an additional 2,862 shares during the last quarter. Kovack Advisors Inc. grew its holdings in shares of Nyxoah by 100.0% during the 4th quarter. Kovack Advisors Inc. now owns 20,000 shares of the company's stock worth $160,000 after purchasing an additional 10,000 shares during the period. LPL Financial LLC acquired a new stake in shares of Nyxoah during the 4th quarter worth about $102,000. Finally, Ameriprise Financial Inc. purchased a new stake in Nyxoah in the 4th quarter valued at about $135,000.
Nyxoah Company Profile
(
Get Free Report)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
See Also
Before you consider Nyxoah, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nyxoah wasn't on the list.
While Nyxoah currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
